242 related articles for article (PubMed ID: 19802013)
1. Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation.
Borbone E; Berlingieri MT; De Bellis F; Nebbioso A; Chiappetta G; Mai A; Altucci L; Fusco A
Oncogene; 2010 Jan; 29(1):105-16. PubMed ID: 19802013
[TBL] [Abstract][Full Text] [Related]
2. Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma.
Chen MC; Huang HH; Lai CY; Lin YJ; Liou JP; Lai MJ; Li YH; Teng CM; Yang CR
Oncotarget; 2016 Jan; 7(1):402-17. PubMed ID: 26587975
[TBL] [Abstract][Full Text] [Related]
3. Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death.
Conticello C; Adamo L; Giuffrida R; Vicari L; Zeuner A; Eramo A; Anastasi G; Memeo L; Giuffrida D; Iannolo G; Gulisano M; De Maria R
J Clin Endocrinol Metab; 2007 May; 92(5):1938-42. PubMed ID: 17327374
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibition modulates E-cadherin expression and suppresses migration and invasion of anaplastic thyroid cancer cells.
Catalano MG; Fortunati N; Pugliese M; Marano F; Ortoleva L; Poli R; Asioli S; Bandino A; Palestini N; Grange C; Bussolati B; Boccuzzi G
J Clin Endocrinol Metab; 2012 Jul; 97(7):E1150-9. PubMed ID: 22563106
[TBL] [Abstract][Full Text] [Related]
5. Different induction of GRP78 and CHOP as a predictor of sensitivity to proteasome inhibitors in thyroid cancer cells.
Wang HQ; Du ZX; Zhang HY; Gao DX
Endocrinology; 2007 Jul; 148(7):3258-70. PubMed ID: 17431003
[TBL] [Abstract][Full Text] [Related]
6. Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells.
Nencioni A; Wille L; Dal Bello G; Boy D; Cirmena G; Wesselborg S; Belka C; Brossart P; Patrone F; Ballestrero A
Clin Cancer Res; 2005 Jun; 11(11):4259-65. PubMed ID: 15930365
[TBL] [Abstract][Full Text] [Related]
7. Metformin synergistically enhances antitumor activity of histone deacetylase inhibitor trichostatin a against osteosarcoma cell line.
Duo J; Ma Y; Wang G; Han X; Zhang C
DNA Cell Biol; 2013 Apr; 32(4):156-64. PubMed ID: 23451817
[TBL] [Abstract][Full Text] [Related]
8. RhoB upregulation leads to either apoptosis or cytostasis through differential target selection.
Marlow LA; Bok I; Smallridge RC; Copland JA
Endocr Relat Cancer; 2015 Oct; 22(5):777-92. PubMed ID: 26206775
[TBL] [Abstract][Full Text] [Related]
9. The histone deacetylase inhibitor trichostatin a promotes apoptosis and antitumor immunity in glioblastoma cells.
Höring E; Podlech O; Silkenstedt B; Rota IA; Adamopoulou E; Naumann U
Anticancer Res; 2013 Apr; 33(4):1351-60. PubMed ID: 23564772
[TBL] [Abstract][Full Text] [Related]
10. Itch/AIP4-independent proteasomal degradation of cFLIP induced by the histone deacetylase inhibitor SAHA sensitizes breast tumour cells to TRAIL.
Yerbes R; López-Rivas A
Invest New Drugs; 2012 Apr; 30(2):541-7. PubMed ID: 21107885
[TBL] [Abstract][Full Text] [Related]
11. A histone deacetylase inhibitor LBH589 downregulates XIAP in mesothelioma cell lines which is likely responsible for increased apoptosis with TRAIL.
Symanowski J; Vogelzang N; Zawel L; Atadja P; Pass H; Sharma S
J Thorac Oncol; 2009 Feb; 4(2):149-60. PubMed ID: 19179889
[TBL] [Abstract][Full Text] [Related]
12. Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer.
Zhang L; Zhang Y; Mehta A; Boufraqech M; Davis S; Wang J; Tian Z; Yu Z; Boxer MB; Kiefer JA; Copland JA; Smallridge RC; Li Z; Shen M; Kebebew E
Oncotarget; 2015 Apr; 6(11):9073-85. PubMed ID: 25940539
[TBL] [Abstract][Full Text] [Related]
13. Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanism.
Hui KF; Chiang AK
Int J Cancer; 2014 Dec; 135(12):2950-61. PubMed ID: 24771510
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells.
Sung ES; Kim A; Park JS; Chung J; Kwon MH; Kim YS
Apoptosis; 2010 Oct; 15(10):1256-69. PubMed ID: 20582477
[TBL] [Abstract][Full Text] [Related]
15. Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.
Altmann A; Markert A; Askoxylakis V; Schöning T; Jesenofsky R; Eisenhut M; Haberkorn U
J Nucl Med; 2012 Nov; 53(11):1764-71. PubMed ID: 23055533
[TBL] [Abstract][Full Text] [Related]
16. Induction of E-cadherin in lung cancer and interaction with growth suppression by histone deacetylase inhibition.
Kakihana M; Ohira T; Chan D; Webster RB; Kato H; Drabkin HA; Gemmill RM
J Thorac Oncol; 2009 Dec; 4(12):1455-65. PubMed ID: 20009910
[TBL] [Abstract][Full Text] [Related]
17. Carfilzomib potentiates CUDC-101-induced apoptosis in anaplastic thyroid cancer.
Zhang L; Boufraqech M; Lake R; Kebebew E
Oncotarget; 2016 Mar; 7(13):16517-28. PubMed ID: 26934320
[TBL] [Abstract][Full Text] [Related]
18. Potential anti-cancer effect of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a novel histone deacetylase inhibitor, for the treatment of thyroid cancer.
Kim SM; Park KC; Jeon JY; Kim BW; Kim HK; Chang HJ; Choi SH; Park CS; Chang HS
BMC Cancer; 2015 Dec; 15():1003. PubMed ID: 26698299
[TBL] [Abstract][Full Text] [Related]
19. Targeting the proteasome as a promising therapeutic strategy in thyroid cancer.
Wunderlich A; Arndt T; Fischer M; Roth S; Ramaswamy A; Greene BH; Brendel C; Hinterseher U; Bartsch DK; Hoffmann S
J Surg Oncol; 2012 Mar; 105(4):357-64. PubMed ID: 22006286
[TBL] [Abstract][Full Text] [Related]
20. HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA).
Mehdi O; Françoise S; Sofia CL; Urs G; Kevin Z; Bernard S; Igor S; Anabela CD; Dominique L; Eric M; Ali O
Pancreatology; 2012; 12(2):146-55. PubMed ID: 22487525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]